Compare ARAY & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | ASRT |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6M | 76.0M |
| IPO Year | 2006 | 2004 |
| Metric | ARAY | ASRT |
|---|---|---|
| Price | $0.39 | $13.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.4M | 42.2K |
| Earning Date | 04-29-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.58 | $16.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $0.51 |
| 52 Week High | $2.10 | $13.90 |
| Indicator | ARAY | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 31.64 | 70.68 |
| Support Level | $0.33 | $0.69 |
| Resistance Level | $0.63 | N/A |
| Average True Range (ATR) | 0.04 | 0.65 |
| MACD | 0.00 | 0.15 |
| Stochastic Oscillator | 27.25 | 86.84 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.